CN105030842A - Application of Bacteroides intestinalis DSM17393 strain - Google Patents

Abstract

The present invention belongs to the field of application of probiotics, in particular to Bacteroides? intestinalis? DSM? Application of the 17393 strain in the preparation of treatment or prevention of obesity. In the present invention, the male littermates of C57/BL6 male SPF mice are randomly divided into a control group and a bacteria-filled group, and given Bacteroides? intestinalis? DSM? The 17393 strain suspension was administered orally, once a day. Then give high-fat diet feeding, test 7 weeks. Through experiments, it has been verified that the strain is very effective in controlling body weight and body fat, and the content of subcutaneous fat in the groin is reduced by 15%, and the content of paraepididymal fat is reduced by 20.9%. The Bacteroides? intestinalis? DSM? The 17393 strain can be used in medicine, pharmaceutical composition, food and feed for treating or preventing obesity.

Description

Application of Bacteroides intestinalis DSM 17393 Strain

technical field

The invention belongs to the application field of probiotics, in particular to the application of Bacteroides intestinalis DSM17393 bacterial strain in treating or preventing obesity.

Background technique

Obesity, as a risk factor for type 2 diabetes, cardiovascular disease and tumors, has become a global social public problem. In the past decade, genome-wide association analysis has discovered more than 100 human obesity susceptibility loci. However, these loci Can only explain a limited number of causes of obesity. Moreover, the current effective treatment methods for obesity are still very limited. Most of the weight-loss drugs approved by the US FDA have been withdrawn from the market due to large side effects or poor effects. It is urgent to develop new weight-loss methods. Another human genome, the gut microbiota genome, is playing an increasingly important role in the development of obesity. Studies have shown that the intestinal flora structure of obese patients is out of balance, the diversity of intestinal bacteria is decreased, and there is an imbalance in the ratio of Bacteroidetes to Deuterics; based on studies in mice, some bacterial types that can reduce body weight have been found, such as Akkermansiamuciniphila1, Bacteroides uniformis CECT77712. These two articles both adopt the method of intragastric administration in mice. On the basis of ordinary C57BL6 mice fed with a high-fat diet, they are given sterile normal saline or bacterial suspension, and intragastric administration every day for 4-8 weeks, and the weight gain is recorded. After the test, body fat, blood sugar, serum and adipose tissue were collected. The results showed that continuous intragastric administration of the two bacteria can resist obesity and body fat increase caused by high-fat diet, reduce blood sugar, and improve systemic and adipose tissue inflammation. The findings of these studies provide an important experimental basis and technical means for the development of probiotics to intervene in obesity.

Therefore, there is an urgent need in this field to develop an effective, new and non-toxic drug for the treatment and prevention of obesity.

Contents of the invention

The purpose of the present invention is to provide the application of the Bacteroides intestinalis DSM17393 strain in the preparation of treatment or prevention of obesity, which relates to the application of drugs, pharmaceutical compositions, food and feed for the treatment or prevention of obesity. Through experiments, the bacterial strain can significantly inhibit the development of high-fat diet The resulting mice gained weight, decreased body fat content and subcutaneous adipose tissue weight. The scope of use of the Bacteroides intestinalis DSM17393 bacterial strain is broadened, and an effective, new, non-toxic and side effect-free medicine, pharmaceutical composition, food and feed for treating and preventing obesity is developed.

The invention relates to the application of Bacteroides intestinalis DSM17393 strain in the preparation of medicines for treating or preventing obesity. Experiments have proved that the Bacteroides intestinalis DSM17393 strain can significantly inhibit the beneficial effect of reducing body fat content and subcutaneous adipose tissue weight. Therefore, this strain is a probiotic for obesity intervention and can be used in the preparation of drugs for treating or preventing obesity.

A pharmaceutical composition for treating or preventing obesity, characterized by comprising: Bacteroides intestinalis DSM17393 strain and pharmaceutically acceptable auxiliary materials. Preferably, when the pharmaceutical composition for treating or preventing obesity is solid, the pharmaceutical composition contains 10 ⁷ -10 ¹² cfu/g of Bacteroides intestinalis DSM17393 strain;

When the pharmaceutical composition for treating or preventing obesity is in a liquid state, the pharmaceutical composition contains 10 ⁷ -10 ¹² cfu/mL of Bacteroides intestinalis DSM17393 strain.

The pharmaceutically acceptable adjuvant is at least one selected from the group consisting of carriers, excipients, diluents, lubricants, wetting agents, emulsifiers, suspension stabilizers, preservatives, sweeteners and spices. Through animal experiments, the pharmaceutical composition can treat or prevent obesity.

The above pharmaceutical composition can be prepared as a medicine for treating or preventing obesity. Preferably, the medicine is in at least one formulation form of granules, capsules, tablets, powders, oral liquids, suspensions and emulsions.

A food for treating or preventing obesity is characterized in that it includes Bacteroides intestinalis DSM17393 strain and food acceptable auxiliary materials. Preferably, when the food is solid, the food contains 10 ⁷ -10 ¹² cfu/g of the Bacteroides intestinalis DSM17393 strain;

When the food for treating or preventing obesity is in a liquid state, the food contains 10 ⁷ -10 ¹¹ cfu/mL of Bacteroides intestinalis DSM17393 strain.

The food acceptable auxiliary material is at least one selected from the group consisting of carriers, excipients, diluents, lubricants, wetting agents, emulsifiers, suspension stabilizers, preservatives, sweeteners and spices.

A feed for treating or preventing obesity is characterized in that it includes Bacteroides intestinalis DSM17393 bacterial strain and acceptable auxiliary materials in feed science.

The beneficial effect of the present invention is: the present invention provides the new use of BacteroidesintestinalisDSM17393 bacterial strain in the field of preparation treatment or prevention of obesity, through experiments, it is verified that BacteroidesintestinalisDSM17393 bacterial strain is very effective in controlling body weight and body fat, and the content of subcutaneous fat in the groin is reduced 15%, and the fat content of the epididymis was reduced by 20.9%. Therefore, the Bacteroides intestinalis DSM17393 strain can be used in medicine, pharmaceutical composition, food and feed for treating or preventing obesity.

Description of drawings

Figure 1 is a comparison chart of the percentage of body weight growth of mice fed with normal diet for 7 weeks.

Figure 2 is a comparison chart of the percentage of body weight gain after 7 weeks of feeding mice with high-fat diet.

Figure 3 is a comparison chart of the percentage of adipose tissue weight in body weight after 7 weeks of feeding mice with high-fat diet.

Detailed ways

Below in conjunction with embodiment, the present invention will be further described:

The rat model used in this example is: select 10-week-old C57/BL6 male SPF mice, all purchased from Shanghai Slack Experimental Animal Co., Ltd. 2-3 mice were housed in an isolation bag in a cage, and they had free access to water and food to maintain a circadian rhythm.

Strain information: Bacteroides intestinalis DSM17393 strain was purchased from German DMS company.

Example 1

The C57/BL6 male SPF level mice were randomly divided into control group and bacteria-instilled group, with 7-10 mice in each group. The control group was given aseptic PBS, once a day; 10 ⁸ -10 ⁹ cfu/mouse, for intragastric administration test, once a day. Then give high-fat diet feeding, test 7 weeks. During the period, the body weight growth rate of the mice was recorded, and the fat content was detected after the experiment.

The body weight and adipose tissue weighing conditions are shown in Table 1 below:

Table 1

As can be seen from the table, after carrying out intragastric administration of BacteroidesintestinalisDSM17393 bacterial strain suspension to mice, body weight and mouse groin subcutaneous fat content and epididymis fat content are significantly increased slowly than mice in the control group, indicating that Bacteroides intestinalisDSM17393 bacterial strain controls body weight and reduces The effect of subcutaneous fat content in the inguinal region of mice and the content of para-epididymal fat was very pronounced.

The above description is only a preferred embodiment of the present invention, but the present invention should not be limited to the content disclosed in this embodiment. Therefore, all equivalents or modifications that do not deviate from the spirit disclosed in the present invention fall within the protection scope of the present invention.

Claims (10)

1. Application of the Bacteroides intestinalis DSM17393 strain in the preparation of a medicament for treating or preventing obesity. 2. A pharmaceutical composition for treating or preventing obesity, characterized by comprising: Bacteroides intestinalis DSM17393 bacterial strain and pharmaceutically acceptable auxiliary materials. 3. The pharmaceutical composition for treating or preventing obesity according to claim 2, characterized in that: when the pharmaceutical composition is solid, the pharmaceutical composition contains 10 ⁷ -10 ¹² cfu/g of the Bacteroides intestinalis DSM17393 strain; When the pharmaceutical composition is in a liquid state, the pharmaceutical composition contains 10 ⁷ -10 ¹¹ cfu/mL of Bacteroides intestinalis DSM17393 strain. 4. The pharmaceutical composition for the treatment or prevention of obesity according to claim 3, wherein the pharmaceutically acceptable adjuvant is selected from carriers, excipients, diluents, lubricants, wetting agents, At least one of an emulsifier, a suspension stabilizer, a preservative, a sweetener, and a fragrance. 5. A medicament for treating or preventing obesity, characterized in that it comprises the pharmaceutical composition according to any one of claims 2-4. 6. The medicine for treating or preventing obesity according to claim 5, characterized in that, the medicine is at least one preparation in granules, capsules, tablets, powders, oral liquids, suspensions and emulsions form. 7. A food for treating or preventing obesity, characterized in that it includes Bacteroides intestinalis DSM17393 strain and food acceptable auxiliary materials. 8. The food for treating or preventing obesity according to claim 7, characterized in that, when the food is solid, the food contains 10 ⁷ -10 ¹² cfu/g of the Bacteroides intestinalis DSM17393 strain; when the food is liquid , the food contains 10 ⁷ -10 ¹¹ cfu/mL of Bacteroides intestinalis DSM17393 strain. 9. The food for treating or preventing obesity according to claim 7, characterized in that, the food acceptable adjuvant is selected from carrier, excipient, diluent, lubricant, wetting agent, emulsifying At least one of additives, suspension stabilizers, preservatives, sweeteners and spices. 10. A feed for treating or preventing obesity, characterized in that it comprises Bacteroides intestinalis DSM17393 strain and feed acceptable auxiliary materials.